Home Alzheimer’s Disease Atezolizumab Plus Cobimetinib Improves Cancer Control for Patients with Biliary Tract Cancer

Atezolizumab Plus Cobimetinib Improves Cancer Control for Patients with Biliary Tract Cancer

Research presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting, held April 27-28, 2020, found that the combination of atezolizumab (Tecentriq) plus cobimetinib (Cotellic) improved cancer control in some patients with biliary tract cancer.1

“We wanted to see if combining the 2 drugs resulted in improved anticancer activity in biliary tract cancer,” Mark Yarchoan, MD, assistant professor of oncology at Johns Hopkins Kimmel Cancer, said in a press release.2 To find out if the combination was effective, Yarchoan and his colleagues decided to compare the benefit of atezolizumab alone vs atezolizumab plus cobimetinib in a randomized study.

Currently, the standard therapy for patients who have advanced disease is a combination of gemcitabine (Gemzar) and cisplatin, however the survival of patients receiving standard treatment is less than 1…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

Recent Comments